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Background: Pulmonary vein isolation (PVI) for atrial ﬁbrillation (AF) is performed with the endoscopically
assisted laser balloon ablation system (EAS). We hypothesized that placement of a circular mapping catheter
(CMC) in the pulmonary vein (PV) distal to the laser balloon during ablation is feasible and safe.
Methods:Out of 58 included patients, 37 underwentmapping-guided EAS PVI, with the CMC inside the PV during
laser ablation, and 21 patients underwent standard EAS PVI, with the CMC outside the PV during laser ablation.
Results:Mean age was 56 years and 81% had paroxysmal AF. In the mapping-guided ablation group, 91% of PVs
were isolated with the CMC in the PV during EAS ablation, isolation was completed in 9% of PVs after the CMC
was removed from the PV. After passing a learning curve in 18 patients, a signiﬁcant drop in unsuccessfully iso-
lated PVs was observed in the mapping guided EAS PVI group (15% to 4%, P= 0.020). No major complications
were seen in the mapping-guided EAS PVI group. However, in the standard EAS PVI group, laser ablation was
complicated by a temporary phrenic nerve palsy in 1 patient. After a median follow-up of 16.7 months,
there was no statistical difference in AF free survival among treatment groups (mapping-guided: 56% vs. 52%,
P= 0.875).
Conclusion:Mapping guidedEAS PVIwith a distal CMC in the PVduring laser ablation is feasible and seems safe as
the standard EAS PVI approach.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The endoscopic laser balloon ablation system (EAS) [1–4] is a
technique that is being used to perform pulmonary vein isolation
(PVI) in the treatment of atrial ﬁbrillation (AF) [4–6]. The EAS consists
of a ﬂexible, compliant balloon for sustained wall contact and a power
adjustable laser beam for ablation independent of tissue contact.
Despite visual guidance, with a standard EAS approach, electrical
disconnection of the PVs from the left atrium could only be achieved
in 70–80%of pulmonary veins (PVs) [7]. Postablation electricalmapping
with a circular mapping catheter (CMC) therefore remains necessary.
When electrical conduction persists after laser ablation, the CMC is
inserted in the PV, followed by insertion of the EAS to close the gaps
in the circumferential ablation lines [4]. However, there is no data avail-
able on the efﬁcacy and safety of CMC-guided EAS PVI. The present
study aims to report feasibility and safety aspects of mapping-guided
EAS ablation with the CMC inside the PV during laser balloon ablation
compared to standard EAS ablation.iology, Dr. Van Heesweg 2, 8025
31 38 4243222.
land Ltd. This is an open access articl2. Methods
Fifty-eight consecutive patientswhounderwent a primoPVI using the
EAS between December 2011 and November 2013 were reviewed and
patient data was collected from a prospective registry. Patients were ran-
domly divided among twodifferent approaches: themapping-guided ap-
proach group, inwhich the CMCwas positioned in the PV during ablation
and the standard ablation group in which the CMC was outside the PV
during ablation. The prospective registry has been approved by the Insti-
tutional Review Board. All patients underwent routine transoesophageal
echocardiography prior to the procedure to rule out left atrial appendage
thrombus. Furthermore, in accordance with local guidelines, patients
stopped using anticoagulants and were ‘bridged’ with low molecular
weight heparin in a weight-dependent dose until the day of ablation.
2.1. The endoscopic laser balloon
The EAS (CardioFocus, Marlborough, MA, USA) is a non-steerable,
compliant balloon catheter. Its characteristics have been described pre-
viously as well as the pre-ablation protocol [8]. In summary, both the
EAS and CMC (Lasso® Biosense Webster Inc., Diamond Bar, CA, USA)
were transeptally inserted in the left atrium under ﬂuoroscopic
guidance. An activated clotting time of 300–350 s was maintainede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ography was performed in all patients. An oesophageal temperature
probe (SensiTherm, St. JudeMedical, USA)was inserted (Fig. 1), and ener-
gy deliverywas instantaneously terminatedwhen temperature exceeded
39.0 °C. During ablation of the right sided PVs, stimulation of the phrenic
nerve (using 20mA at 2.9 ms) was performed, with immediate cessation
of energy delivery once capture was diminished or lost.
2.2. Mapping-guided ablation
In the mapping-guided approach group, the CMC was ﬁrst posi-
tioned into the PV. Previously recorded templates of PV potentials
were used to assure correct placement of the CMC. Secondly, the EAS
catheter was inﬂated in the same PV proximal to the CMC (Fig. 1). Dur-
ing inﬂation the blind spot of the EAS was positioned over the shaft of
the CMC (Fig. 2). Thereafter, an almost complete circular ablation was
performed while observing the PV potentials of the mapping catheter.
The ablation circle was completed by rotating the EAS and the CMC to
expose the previously obscured atrial tissue, i.e. ‘blind-spot’. A full circle
was always performed, also when PVI occurred during ablation. When,
after a full ablation circle, electrical connection between the LA and the
PV still persisted, gap ablation was performed, as described by previous
reports [4]. When a PV was insufﬁciently occluded for circular ablation
because of interference of the CMC, the CMC was removed from the
PV, and an ablation circle was completed.
2.3. Standard laser balloon ablation
In the standard approach, the EAS was manoeuvred to each PV osti-
um. PV occlusionwas attempted by varying balloon inﬂation size until a
ring of atrial myocardium antral to the PV was exposed. Laser energy
was delivered to the exposed ring of atrial tissue (Fig. 2). The ablation
circle was completed by rotating the EAS to expose the previously ob-
scured atrial tissue, i.e. ‘blind-spot’. After a full circle was completed,Fig. 1. Fluoroscopic image of the setup of the endoscopic laser balloon system (PA view).
The CMCwas inserted transseptally into the left atrium and placed in the left superior pul-
monary vein (LSPV). The laser balloon catheterwas also inserted transseptally into the left
atrium and positioned in the LSPV proximal to the CMC. The temperature probe was posi-
tioned in the oesophagus. The quadripolar catheter was positioned in the coronary sinus.the EAS was retracted from the PV. The CMC was introduced to assess
persistent electrical connection between the PV and the LA. If any
existed, the EAS was re-introduced to the PV, and additional lesions
were applied by the operator to close gaps in the PV antral ablation
lines. No adenosine testing was performed.
2.4. Follow-up
Patients visited the outpatient clinic at 3, 6, 12 and 24 months after
PVI, including 24-hour Holter ECG. AF recurrence was deﬁned in accor-
dancewith current EuropeanAF ablation guidelines [9]. In case of symp-
toms, patients were immediately referred to acquire an ECG. 3 months
after PVI, an attempt was made in all patients to cease AADs.
2.5. Study endpoints
Theprimary endpoint of our studywas acute PVI using themapping-
guided or the standard approach. Secondary endpoints were procedure
time, ablation time and ﬂuoroscopy time. Complications were deﬁned
in accordance with European guidelines [9].
2.6. Statistical analysis
Patients were appointed by the type of procedure (mapping-guided
approach versus standard). Continuous variables were expressed
as mean with standard deviation in case of normal distribution.
Signiﬁcance in differences was analysed by the Mann–Whitney U test.
Categorical data were expressed as numbers and percentages and
compared with Chi-square test. The difference in AF free survival
was assessed with a log-rank test. Statistical analysis was performed
using IBM SPSS statistics version 20 (IBM Inc., Armonk, NY, USA). A
P-value of ≤0.05 was considered statistically signiﬁcant. The artwork
in Fig. 2 was created using Adobe Photoshop CS2 (Adobe Inc., San
Jose, CA, USA).
3. Results
Fifty-eight consecutive patients were included, mapping-guided PVI
was performed in 37 patients. Baseline characteristics were comparable
between treatment groups, as displayed in Table 1.
3.1. Efﬁcacy of PVI using the mapping-guided versus standard approach
In 148 PVswhere isolationwas attemptedwith themapping-guided
EAS PVI approach, isolation of 134 PVs (91%) was accomplished with
the CMC being positioned inside the PV during ablation. Due to subop-
timal PV occlusion with the endoscopic laser balloon, the CMC was
removed in 14 PVs (10 patients) and all PVs were successfully isolated
with the CMC outside the PV. There was no signiﬁcant difference
among the PVs with suboptimal occlusion (P= 0.623): 4 left superior
PVs, 2 left inferior PVs, 3 right superior PVs and 5 right inferior PVs. Of
note, in the ﬁrst 18 patients in the mapping guided EAS PVI group, 11
PVs could not be isolated with the CMC in the PV, compared to 3 in
the last 18 patients (P= 0.020). In patients treated with the standard
EAS PVI approach, 84/85 PVs were isolated (98.8%). In 1 common left
sided PV, isolation could not be achieved due to oesophageal tempera-
ture rise. One procedure in the standard approach group was converted
to RF ablation, after right sided PVablationwas complicated by a tempo-
rary phrenic nerve palsy.
3.2. Procedural characteristics
There was no signiﬁcant difference among treatment groups in
terms of procedure duration and ﬂuoroscopy time. However, ablation
time was signiﬁcantly shorter in the mapping-guided approach group
Fig. 2. Panels a and b. Panel a displays the endoscopic view from the EAS in the left superior pulmonary vein (LSPV)with the CMC in the PV, viewing directly into the PV. First, the CMCwas
positioned in the PV. Then, the EAS was positioned proximally in the same PV and inﬂated until a white ring of atrial tissue (PV antrum) was visualized, indicating ﬁxation of the laser
balloon and optimal balloon-tissue contact. The EAS catheter shaft was positioned over the CMC's shaft. Panel b shows the EAS shaft (yellow), laser aiming beam (green), exposed PV an-
trum (grey) blood distally in the PV (red) and a part of the CMC (blue). Panels c and d. Electrical signals before (c) and during (d) laser ablation with the CMC (Lasso, Biosense Webster,
USA) positioned distal to the laser balloon in the LSPV. The top three electrograms are standard ECG leads (I, III and V1), the middle 5 are PV potentials recorded with the CMC, the two
coronary sinus bipolar electrograms are at the bottom. In panel c, the electrical potentials before laser balloon ablation are shown. The top three electrograms are standard ECG leads (I, III
and V1). The bipolar PV potentials recordedwith decapolar CMC are shown. The LSPV prior to ablation depicted large PV potentials (arrows). In panel D the change in electrical potentials
during PV isolation are depicted. Note the conduction delay at the veno-atrial junction compared to the template in panel c (arrows), followed by conduction block (asterisk).
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Table 2 displays the procedural characteristics among treatment groups.3.3. Safety
There were no complications among patients treated with the
mapping-guided approach. In the standard ablation group, one patient
suffered from a temporary phrenic nerve palsy. This patient has fullyTable 1
Baseline characteristics.
Mapping-guided approach (n= 37)
Age (years) 54.8 ± 10.1
Sex Female (%) 9 (24%)
BMI (kg/m2) 27.2 ± 4.0
Non-paroxysmal AF 7 (19%)
AF duration (years) 6.1 (±5.7)
Hypertension 27 (73%)
Diabetes 1 (3%)
Failed AADs 1.4 (0–4)
LA dimension in PSLAX (mm) 41.1 (±4.0)
LVEF (%) 58.4 (±3.6)
Data are presented as absolute numbers or means with ± their SD, with percentages or range
denotes body mass index, AF; atrial ﬁbrillation, AAD; anti-arrhythmic drugs, LA; left atrium, PSrecovered after 6 months. There have been no patients suffering from
thromboembolic events in either ablation approach.
3.4. Follow-up
After a median follow-up of 16.7 (q1–q3: 11.2–19.9) months, 33
(57%) patients were still free of AF recurrences after a single EAS PVI
attempt. None of the patients who were free of AF were using AADs
at the end of the study period. AF free survival was 55.9% in theStandard (n= 21) P-value Total group
(n= 58)
58.7 ± 11.8 0.178 56.2 ± 10.8
7 (33%) 0.461 16 (28%)
26.5 ± 3.3 0.508 26.9 ± 3.6
4 (14%) 0.990 11 (19%)
7.4 (±7.1) 0.459 6.6 ± 6.2
11(52%) 0.113 38 (66%)
2 (10%) 0.260 3 (5%)
1.4 (0–3) 0.952 1.4 (0–4)
41.1 (±4.0) 0.984 41.1 (±3.9)
59.4 (±2.4) 0.239 58.7 (±3.3)
s where appropriate. P-values are between mapping-guided and standard approach. BMI
LAX; parasternal long axis view, LVEF; left ventricular ejection fraction.
Table 2
Procedural characteristics.
Mapping-guided
approach
(n= 37)
Standard
approach
(n= 21)
p-Value Total
group
(n= 58)
Procedure time (min) 179 (±42) 170 (±40) 0.469 175 (±41)
Ablation time (min) 51 (±25) 71 (±28) 0.017 59 (±28)
Fluoroscopy time (min) 35 (±9) 34 (±12) 0.849 35 (±10)
Data are presented as means± their SD. P-values are betweenmapping-guided and stan-
dard approach.
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group (P= 0.875), as displayed in Fig. 3.
4. Discussion
The present study indicates that it is feasible and safe to perform a
circumferential PVI using the mapping-guided EAS PVI approach with
a CMC inside the PV during EAS ablation, with a comparable AF free sur-
vival. Of note, ablation time was signiﬁcantly reduced in the mapping-
guided approach group. Nevertheless, in 9% of PVs, the CMC was
removed from the PV during ablation due to suboptimal PV occlusion.
4.1. Pulmonary vein isolation
The present study showed that a mapping-guided EAS ablation re-
sulted in an acutely isolated PV in 134 out of 148 attempted PVs. In 14
PVs, PV occlusion could not be achieved with the CMC in the PV during
ablation, and the CMC needed to be removed from the PV. Of note, there
seemed to be a learning curve present, and in the last 18 patients of the
mapping guided EAS PVI group, only 3 PVs could not be isolated with
the CMC in the PV. A learning curve was also observed in a series of
150 EAS patients [10].
4.2. Complications
There were no complications in the mapping-guided approach EAS
PVI group, although a studywith a larger patient population is necessary
to demonstrate the safety of mapping-guided ablation. Of note, in order
to prevent complications, it seems important to place the blind spot of
the EAS over the shaft of the circular ablation catheter to prevent energy
application on the CMC shaft itself, since this may result in overheating
of the catheter shaft and thereby thrombus formation or balloon
perforation.Fig. 3. AF free survival after EAS PVI. This ﬁgure depicts the AF free survival after EAS PVI
for both treatment groups. AF free survival is not signiﬁcantly different among treatment
groups, P= 0.875.4.3. Potential advantages
Witnessing conduction slowing and block of PV potentials during
PVI is a deﬁnitive argument in achieving acute PVI. For example, in the
standard EAS PVI approach, placement of the CMC too distally in the
PV after removal of the EAS from the PVmay result in erroneously iden-
tifying a PV as being isolated. Moreover, the obviation of removal and
re-introduction of the EAS during gap mapping avoids the possibility
of applying ablation circles at different depths at the PV antrum. Poten-
tially, multiple circular ablation lesions at different depths at the PV an-
trum in the standard approach can result in insufﬁciently overlapping
ablation lesions and thereby inﬂuence AF free survival. Furthermore,
the ablation time was signiﬁcantly shorter in the mapping-guided
approach group. Although this study was not aimed at identifying
the mechanism for this difference, potentially, ablation with the
mapping-guided approach is more efﬁcient and reduces the need for
gap ablations.
4.4. Future perspectives
This feasibility study with preliminary data shows that EAS ablation
can be performedwith themapping-guided approach. Furthermore, we
did not observe any complications related to the mapping-guided
approach, suggesting a favourable safety proﬁle, although the data is
preliminary. The EAS is a relatively novel technology which has been
proven to be effective and safe. There is a clear clinical need for an endo-
scopic laser balloonwith PVmapping capabilities. Potentially, an adjust-
ed endoscopic laser balloon with incorporation of mapping electrodes
can result in reduction of procedure times and increased long-term
efﬁcacy.
4.5. Limitations
With regards to interpreting our data, the following limitations
should be considered. Patients were not randomized to the different
ablation procedures. Instead, patients were randomly allocated to PVI
approaches. Current study consists of a limited sample size. In 10 pa-
tients from the mapping-guided approach group, a standard ablation
approach was performed in 1 or 2 PVs. Excluding these patients from
analysis did not affect the primary endpoint.
5. Conclusion
In conclusion, mapping-guided EAS PVI with the laser balloon is a
feasible and safe technique. This study did not show an increase in com-
plications, although larger studies are necessary to conﬁrm safety and
outcome issues.
Conﬂict of interest
None declared.
Funding
None.
Acknowledgements
We would like to thank Ms. Vera Derks for excellent editorial
assistance.
References
[1] Reddy VY, Neuzil P, Themistoclakis S, Danik SB, Bonso A, Rossillo A, et al. Visually-
guided balloon catheter ablation of atrial ﬁbrillation: experimental feasibility and
ﬁrst-in-human multicenter clinical outcome. Circulation 2009;120:12–20.
72 P. Gal et al. / IJC Heart & Vasculature 8 (2015) 68–72[2] Dukkipati SR, KuckKH,Neuzil P,Woollett I, Kautzner J,McElderryHT, et al. Pulmonary
vein isolation using a visually guided laser balloon catheter: the ﬁrst 200-patient
multicenter clinical experience. Circ Arrhythm Electrophysiol 2013;6:467–72.
[3] Dukkipati SR, Neuzil P, Skoda J, Petru J, d'Avila A, Doshi SK, et al. Visual balloon-
guided point-by-point ablation: reliable, reproducible, and persistent pulmonary
vein isolation. Circ Arrhythm Electrophysiol 2010;3:266–73.
[4] Schmidt B, Metzner A, Chun KR, Leftheriotis D, Yoshiga Y, Fuernkranz A, et al. Feasi-
bility of circumferential pulmonary vein isolation using a novel endoscopic ablation
system. Circ Arrhythm Electrophysiol 2010;3:481–8.
[5] Bordignon S, Chun KJ, Gunawardene M, Fuernkranz A, Urban V, Schulte-Hahn B,
et al. Comparison of balloon catheter ablation technologies for pulmonary vein
isolation: the laser versus cryo study. J Cardiovasc Electrophysiol 2013;24:987–94.
[6] Bordignon S, Chun KR, Gunawardene M, Urban V, Kulikoglu M, Miehm K, et al.
Energy titration strategies with the endoscopic ablation system: lessons from the
high-dose vs low-dose laser ablation study. Europace 2013;15:685–9.[7] Schmidt B, Gunawardene M, Urban V, Kulikoglu M, Schulte-Hahn B, Nowak B, et al.
Visually guided sequential pulmonary vein isolation: insights into techniques and
predictors of acute success. J Cardiovasc Electrophysiol 2012;23:576–82.
[8] Gal P, Smit JJ, Adiyaman A, Ramdat Misier AR, Delnoy PP, Elvan A. First dutch expe-
rience with the endoscopic laser balloon ablation system for the treatment of atrial
ﬁbrillation. Neth Heart J 2015;23:96–9.
[9] Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/
ECAS expert consensus statement on catheter and surgical ablation of atrial ﬁbrillation:
recommendations for patient selection, procedural techniques, patient management
and follow-up, deﬁnitions, endpoints, and research trial design. Europace 2012;14:
528–606.
[10] Perrotta L, Bordignon S, Dugo D, Furnkranz A, Chun KJ, Schmidt B. How to learn
pulmonary vein isolation with a novel ablation device: learning curve effects using
the endoscopic ablation system. J Cardiovasc Electrophysiol 2014;25:1293–8.
